GHRP-6 5mg

Name: GHRP-6 5mg
SKU: PL-5MG-PF01
Price: 33.00 USD
Availability: InStock

Brands PeptideLion

$33.00

out of stock

Sku:

PL-5MG-PF01

Brands: PeptideLion

Description

Overview:

Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone-releasing hormone (GHRH) in that they share no sequence relation and derive their function through the activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor’s natural endogenous ligand, and it has been renamed the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

GHRP-6 Effects:

Increased collagen production
Better repair of internal organs
Increased healing capacity
Increased energy
Improved sleep
Increase in lean body mass
Reduced body fat

Scientific Information:

Growth hormone-releasing peptide (GHRP-6) is a synthetic hexapeptide that specifically stimulates the secretion of growth hormone (GH) by pituitary somatotrophs. The precise intracellular mechanism by which this is achieved has not been deciphered although it is known to involve protein kinase C (PKC) and Ca2+ but to be cAMP-independent. We have used cell cultures of human pituitary somatotrophinomas to demonstrate the powerful effects of GHRP-6 on membrane phosphatidylinositol (PI) turnover, a second messenger system that leads to activation of PKC and mobilization of intracellular Ca2+ reserves. Incubation of somatotrophinoma cells with GHRP-6 led to a dose-dependent stimulation of the rate of PI turnover.

GH secretion increased in parallel. Researchers detected effects after just 15 minutes of incubation, with the response peaking at 2 hours. GHRP-6 stimulated PI turnover in all 8 tumors examined, showing increases ranging from 2.1 to 7.9-fold. The stimulation of GH secretion by GHRP-6 occurred regardless of the presence of gsp oncogenes, highlighting the cAMP-independent nature of its effects. These findings provide evidence that GHRP-6 stimulates GH secretion by activating the PI second messenger system, supporting earlier research that shows PKC and Ca2+ play central roles in mediating GHRP-6’s effects.

The family of peptidyl growth hormone (GH) secretagogues with broad cytoprotective properties came to light by the American endocrinologist Cyril Bowers, who observed that chemical analogs of enkephalin amide showed GH-releasing activity upon their incorporation into pituitary cultures. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) appeared as the first in-line synthetic peptide that specifically elicited GH dosage-related release in vitro and in vivo. GHRP-6 exhibits a potent cytoprotective effect, extending tissue viability during acute ischemia/reperfusion episodes in different organs (e.g. small bowel, liver, kidneys). This peptide has also shown antioxidant activity in preclinical experimental models, and may partially contribute to reducing myocardial ischemic damage. Thus, pathologies associated with ischemia or some types of tissue damage may potentially benefit from treatment with this promising therapeutic candidate.

Research Highlights:

Based on the potential benefits of the growth hormone-releasing peptide (GHRP)-6 on muscle function, researchers tested the newly synthesized GHRP-6-biotin conjugate on cultured myoblast cells. They observed increased expression of myogenic marker proteins in the GHRP-6-biotin conjugate-treated cells. Additionally, the cells showed higher levels of insulin-like growth factor-1 and collagen type I. The GHRP-6-biotin conjugate also boosted metabolic activity, indicated by increased concentrations of energy metabolites like ATP and lactate, along with higher enzymatic activity of lactate dehydrogenase and creatine kinase. Binding protein analysis revealed potential targets for the GHRP-6-biotin conjugate’s action, including desmin, actin, and zinc finger protein 691. These results suggest that the newly synthesized GHRP-6-biotin conjugate stimulates myogenic activity, at least partially by promoting collagen type I synthesis and other key proteins. The practical application of GHRP-6-biotin conjugate could improve muscle conditions.